search
Back to results

Lithotripsy and Analgesia With 3D Hypnosis Mask (LAHMA)

Primary Purpose

Renal Calculi, Pain

Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Hypnosis 3D virtual reality headset
Sponsored by
Assistance Publique - Hôpitaux de Paris
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Renal Calculi focused on measuring therapeutic virtual reality, hypnosis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

- Shock wave lithotripsy and outpatient surgery

Exclusion Criteria:

  • Epilepsy
  • Deafness, Blindness
  • Schizophrenia, Hallucinations
  • No french-speaking
  • Autistic
  • Motion sickness

Sites / Locations

  • Assistance Publique Hôpitaux de Paris, Necker
  • Assistance Publique Hôpitaux de Paris, Hôpital Européen Georges PompidouRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

3D virtual reality

Control

Arm Description

Use of Hypnosis 3D virtual reality headset

Standard of care : no hypnosis 3D virtual reality headset but a noise cancelling headphone

Outcomes

Primary Outcome Measures

Remifentanil use
Remifentanil consumption (microgram) during shock wave lithotripsy

Secondary Outcome Measures

Maximal level of pain during shock wave lithotripsy
Use of analogical visual pain self-assessment at the end of the shock wave lithotripsy

Full Information

First Posted
March 19, 2021
Last Updated
April 14, 2023
Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
GAMIDA, Healthy Mind
search

1. Study Identification

Unique Protocol Identification Number
NCT04869293
Brief Title
Lithotripsy and Analgesia With 3D Hypnosis Mask
Acronym
LAHMA
Official Title
Assessment of Analgesia Through Hypnosis With 3D Virtual Reality During Extra-corporeal Lithotripsy (LAHMA)
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Recruiting
Study Start Date
April 15, 2021 (Actual)
Primary Completion Date
February 2024 (Anticipated)
Study Completion Date
February 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
GAMIDA, Healthy Mind

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The study is a randomised trial of hypnosis with 3D virtual reality headset (intervention group) versus control group with no hypnosis and no virtual reality headset to compare remifentanil consumption during shock wave lithotripsy.
Detailed Description
The study is for patients undergoing shock wave lithotripsy in outpatient surgery unit. It is proposed that using hypnosis with 3D virtual reality headset will reduce the requirements for intravenous remifentanil in a randomised controlled trial of one hundred and six patients. Remifentanil is an opioid commonly used for lithotripsy. Shock wave lithotripsy is a commonly performed procedure associated with moderate pain and anxiety, in outpatient surgery unit. Opioids can cause unfavourable side-effects, most notably respiratory depression, sedation, nausea and vomiting It is expected that by using 3D virtual reality to reduce pain and anxiety, there will be a reduced requirement for intravenous remifentanil. The study will measure the dose of remifentanil required by patients randomised to receive either hypnosis with 3D virtual reality headset (intervention) or no hypnosis and no 3D virtual reality headset (control group). Patients will be followed up prior to hospital discharge to assess their remifentanil use and pain, anxiety, comfort and their satisfaction with 3D virtual reality headset. This new device is a non-pharmacological adjunct and can reduce pain intensity during procedure, reduce opioid use and length of stay in hospital and improve the patient experience whilst potentially reducing complications of intravenous opioid. This study findings will be of interest for patients involved in surgery or investigative procedures normally carried out with intravenous opioids or sedation.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Renal Calculi, Pain
Keywords
therapeutic virtual reality, hypnosis

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
106 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
3D virtual reality
Arm Type
Experimental
Arm Description
Use of Hypnosis 3D virtual reality headset
Arm Title
Control
Arm Type
No Intervention
Arm Description
Standard of care : no hypnosis 3D virtual reality headset but a noise cancelling headphone
Intervention Type
Device
Intervention Name(s)
Hypnosis 3D virtual reality headset
Intervention Description
3D experience to journey through a natural and therapeutic environment. Immersion is amplified by the realism of 3D environment, a soothing sound atmosphere and specific medical hypnosis.
Primary Outcome Measure Information:
Title
Remifentanil use
Description
Remifentanil consumption (microgram) during shock wave lithotripsy
Time Frame
Hour 1
Secondary Outcome Measure Information:
Title
Maximal level of pain during shock wave lithotripsy
Description
Use of analogical visual pain self-assessment at the end of the shock wave lithotripsy
Time Frame
Hour 1

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: - Shock wave lithotripsy and outpatient surgery Exclusion Criteria: Epilepsy Deafness, Blindness Schizophrenia, Hallucinations No french-speaking Autistic Motion sickness
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Darless Clausse, MD
Phone
331 56 09 54 11
Email
darless.clausse@aphp.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Natacha Nohilé
Phone
331 56 09 59 82
Email
natacha.nohile@aphp.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Darless Clausse, MD
Organizational Affiliation
Hôpital européen Geroges-Pompidou
Official's Role
Principal Investigator
Facility Information:
Facility Name
Assistance Publique Hôpitaux de Paris, Necker
City
Paris
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Darless Clausse, MD
Facility Name
Assistance Publique Hôpitaux de Paris, Hôpital Européen Georges Pompidou
City
Paris
State/Province
Île-de-France
ZIP/Postal Code
75015
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Darless CLAUSSE, MD
Phone
331 56 09 54 11
Email
darless.clausse@aphp.fr

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Individual participant data (IPD) that underlie results in publication could be shared. IPD detailed in the protocol of a planned metaanalysis could be shared
IPD Sharing Time Frame
Two years after the last publication
IPD Sharing Access Criteria
Data sharing must be accepted by the sponsor and the PI based on scientific project and scientific involvement of the PI team. Collaboration will be fostered. Data sharing must respect the agreements made with funders. Teams wishing obtain IPD must meet the sponsor and IP team to present scientific (and commercial) purpose, IPD needed, format of data transmission, and timeframe. Technical feasibility and financial support will be discussed before mandatory contractual agreement. Processing of shared data must comply with European General Data Protection Regulation (GDPR).
Citations:
PubMed Identifier
31136330
Citation
Eijlers R, Utens EMWJ, Staals LM, de Nijs PFA, Berghmans JM, Wijnen RMH, Hillegers MHJ, Dierckx B, Legerstee JS. Systematic Review and Meta-analysis of Virtual Reality in Pediatrics: Effects on Pain and Anxiety. Anesth Analg. 2019 Nov;129(5):1344-1353. doi: 10.1213/ANE.0000000000004165.
Results Reference
background
PubMed Identifier
29395400
Citation
Scapin S, Echevarria-Guanilo ME, Boeira Fuculo Junior PR, Goncalves N, Rocha PK, Coimbra R. Virtual Reality in the treatment of burn patients: A systematic review. Burns. 2018 Sep;44(6):1403-1416. doi: 10.1016/j.burns.2017.11.002. Epub 2018 Feb 1.
Results Reference
background
PubMed Identifier
30052655
Citation
Chan E, Foster S, Sambell R, Leong P. Clinical efficacy of virtual reality for acute procedural pain management: A systematic review and meta-analysis. PLoS One. 2018 Jul 27;13(7):e0200987. doi: 10.1371/journal.pone.0200987. eCollection 2018.
Results Reference
background

Learn more about this trial

Lithotripsy and Analgesia With 3D Hypnosis Mask

We'll reach out to this number within 24 hrs